This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.
June 04, 2019
Strongbridge Biopharma plc Strengthens Senior Leadership Team with Key Promotion and Appointment
June 03, 2019
New Data from Oncopeptides Phase 1/2 O-12-M1 Trial Evaluating Melflufen in RRMM Presented at 2019 ASCO Annual Meeting
June 03, 2019
Carisma Therapeutics Names Dr. Robert Petit as Chief Scientific Officer
June 03, 2019
Nordic Nanovector: European patent granted for Betalutin® or Humalutin® in combination with anti-CD20 antibodies for treating NHL
June 03, 2019
Targovax announces publication of in vivo abscopal effect of ONCOS-102 and Keytruda combination
June 03, 2019
Rainier Therapeutics Announces Results from First Interim Analysis of the FIERCE-22 Trial of Vofatamab in Combination with Pembrolizumab in Patients with Metastatic Urothelial Cell Carcinoma (Bladder Cancer)
May 29, 2019
Sustained bilateral improvement from GenSight Biologics’ REVERSE Phase III clinical trial represents transformative therapeutic benefit for patients, Key Opinion Leaders conclude
May 23, 2019
Targovax to fully focus on ONCOS oncolytic virus program
May 23, 2019
Targovax announces median and three-year overall survival for TG01 trial in resected pancreatic cancer
May 23, 2019
Nordic Nanovector ASA – Results for the First Quarter 2019